Brief: BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501
10/04/2024 12:07
April 10 (Reuters) - BioXcel Therapeutics Inc BTAI.O :
* BIOXCEL THERAPEUTICS INC - COMPANY PLANS TO INITIATE TRIAL
FOLLOWING RECENT MEETING WITH FDA
* BIOXCEL THERAPEUTICS ANNOUNCES TRANQUILITY IN-CARE PIVOTAL
PHASE
3 TRIAL PLAN WITH BXCL501 FOR AGITATION ASSOCIATED WITH
ALZHEIMER’S DEMENTIA
Source text for Eikon: ID:nGNX9pbMht
Further company coverage: BTAI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty